David I. Quinn, MBBS, PhD, on Urothelial Cancer: Results from KEYNOTE-045

2017 ASCO Annual Meeting
Tweet this page

David I. Quinn, MBBS, PhD, of the University of Southern California, gives his expert perspective on the planned survival analysis from a phase III open-label study of pembrolizumab vs paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer. (Abstract 4501)

Advertisement

Advertisement



Advertisement